MYGN

5.86

2.82% -0.17

Dopo l'orario di chiusura: 5.86

Myriad Genetics Inc (MYGN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché MYGN Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$6.03

Aprire:

$6.09

Volume 24 ore:

1.14M

Relative Volume:

0.72

Capitalizzazione di mercato:

$553.47M

Reddito:

$829.00M

Utile/perdita netta:

$-399.90M

Rapporto P/E:

-1.3578

EPS:

-4.3159

Flusso di cassa netto:

$-23.20M

1 W Prestazione:

+2.63%

1M Prestazione:

+28.23%

6M Prestazione:

-11.61%

1 anno Prestazione:

+10.78%

Intervallo 1D:

$5.775

$6.15

Intervallo di 1 settimana:

$5.725

$6.255

Portata 52W:

$3.53

$8.59

Myriad Genetics Inc Stock (MYGN) Company Profile

Nome

Myriad Genetics Inc

Settore

Healthcare (1094)

Industria

Diagnostics & Research (48)

Telefono

801-584-3600

Indirizzo

322 NORTH 2200 WEST, SALT LAKE CITY, UT

Dipendente

2,700

Cinguettio

@myriadgenetics

Prossima data di guadagno

2026-08-04

Ultimi documenti SEC

MYGN's Discussions on Twitter

Compare MYGN vs TMO, DHR, IDXX, NTRA, A

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
MYGN Myriad Genetics Inc	5.86	569.52M	829.00M	-399.90M	-23.20M	-4.3159
TMO Thermo Fisher Scientific Inc	516.62	192.35B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	194.19	137.04B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	570.25	44.57B	4.45B	1.10B	1.06B	13.59
NTRA Natera Inc	281.27	40.64B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	131.14	36.89B	7.23B	1.41B	1.09B	4.979

Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-05-21	Downgrade	Scotiabank	Sector Outperform → Sector Perform
2025-05-08	Downgrade	Wolfe Research	Outperform → Peer Perform
2025-05-07	Downgrade	Wells Fargo	Overweight → Equal Weight
2025-04-09	Downgrade	Guggenheim	Buy → Neutral
2025-03-12	Aggiornamento	Piper Sandler	Neutral → Overweight
2025-02-12	Iniziato	Craig Hallum	Buy
2024-12-10	Iniziato	UBS	Neutral
2024-12-09	Downgrade	Leerink Partners	Outperform → Market Perform
2024-09-19	Iniziato	Morgan Stanley	Equal-Weight
2024-08-28	Iniziato	Wells Fargo	Overweight
2024-06-27	Iniziato	Scotiabank	Sector Outperform
2024-06-03	Ripresa	Jefferies	Underperform
2024-05-08	Aggiornamento	Leerink Partners	Market Perform → Outperform
2023-12-21	Ripresa	Piper Sandler	Neutral
2023-12-19	Iniziato	Wells Fargo	Equal Weight
2023-12-14	Iniziato	Guggenheim	Buy
2023-12-13	Iniziato	Wolfe Research	Outperform
2023-07-05	Ripresa	JP Morgan	Underweight
2023-05-23	Aggiornamento	Goldman	Sell → Buy
2023-01-18	Aggiornamento	Raymond James	Mkt Perform → Outperform
2022-10-06	Iniziato	Stephens	Equal-Weight
2021-10-15	Ripresa	Cowen	Market Perform
2021-06-15	Iniziato	Raymond James	Mkt Perform
2021-06-03	Iniziato	Goldman	Sell
2019-09-26	Downgrade	BofA/Merrill	Neutral → Underperform
2019-08-14	Downgrade	Piper Jaffray	Overweight → Neutral
2019-08-02	Aggiornamento	BofA/Merrill	Underperform → Neutral
2019-08-01	Aggiornamento	Barclays	Underweight → Equal Weight
2019-07-29	Downgrade	Needham	Strong Buy → Hold
2019-07-09	Downgrade	Cowen	Outperform → Market Perform
2019-03-12	Reiterato	Needham	Strong Buy
2019-01-03	Iniziato	Needham	Strong Buy
2018-11-30	Aggiornamento	Goldman	Sell → Neutral
2018-10-10	Aggiornamento	Piper Jaffray	Neutral → Overweight
2018-07-11	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2018-03-21	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2018-01-29	Iniziato	Goldman	Sell
2018-01-22	Reiterato	Barclays	Equal Weight
2018-01-05	Iniziato	BTIG Research	Buy
2017-10-02	Ripresa	Leerink Partners	Mkt Perform
2017-08-09	Reiterato	Barclays	Equal Weight
2017-02-08	Aggiornamento	Ladenburg Thalmann	Sell → Neutral
2017-01-18	Iniziato	Deutsche Bank	Sell
2016-10-10	Downgrade	Ladenburg Thalmann	Neutral → Sell

Mostra tutto

Myriad Genetics Inc Borsa (MYGN) Ultime notizie

Jul 02, 2026

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris Biopsy Test in Localized Prostate Cancer - 富途牛牛

Jul 02, 2026

MYGN Stock Price, Quote & Chart - ChartMill

Jul 02, 2026

Jul 01, 2026

SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS - BioSpace

Jul 01, 2026

Jun 30, 2026

Sera Prognostics adds former Myriad Genetics CEO to board By Investing.com - Investing.com South Africa

Jun 30, 2026

MYGNMyriad Genetics Inc Latest SEC Filings - Finviz

Jun 30, 2026

Sera Prognostics adds former Myriad Genetics CEO to board - Investing.com

Jun 30, 2026

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance

Jun 30, 2026

Jun 29, 2026

Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock? - Yahoo Finance

Jun 29, 2026

Jun 27, 2026

(MYGN) Risk Channels and Responsive Allocation - Stock Traders Daily

Jun 27, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review

Jun 27, 2026

Enterprise value to revenue forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView

Jun 26, 2026

Enterprise value to revenue forward of Myriad Genetics, Inc. – LS:897518 - TradingView

Jun 26, 2026

MYGN Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Myriad Genetics, Inc. Actuals & Estimates (FWB:MYD) - TradingView

Jun 26, 2026

Jun 25, 2026

Myriad Genetics clears analyst hurdle, shares steady on NASDAQ - AD HOC NEWS

Jun 25, 2026

MYD Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 24, 2026

Why Is Myriad Genetics (MYGN) Stock Rocketing Higher Today - Yahoo Finance

Jun 24, 2026

Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication - Sahm

Jun 24, 2026

Jun 23, 2026

Director at Myriad Genetics (MYGN) reports 195,507-share Common Stock stake - Stock Titan

Jun 23, 2026

Myriad Genetics expands cancer detection test availability By Investing.com - Investing.com Australia

Jun 23, 2026

Form 8K Myriad Genetics Inc For: 23 June By Investing.com - Investing.com Australia

Jun 23, 2026

MYGN PE Ratio & Valuation, Is MYGN Overvalued - Intellectia AI

Jun 23, 2026

Myriad Genetics expands cancer detection test availability - Investing.com

Jun 23, 2026

Myriad Genetics director Daniel Skovronsky resigns from board By Investing.com - Investing.com Australia

Jun 23, 2026

Myriad Genetics director Daniel Skovronsky resigns from board - Investing.com UK

Jun 23, 2026

MYRIAD GENETICS, INC. 8-K Filing: Key Company Information and SEC Compliance Details for June 2026 - Minichart

Jun 23, 2026

Myriad widens cancer test access as breast study bolsters its case - Stock Titan

Jun 23, 2026

Board member Skovronsky exits Myriad Genetics (NASDAQ: MYGN) - Stock Titan

Jun 23, 2026

Jun 22, 2026